Organon & Co. (OGN)
Company Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally.
Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio.
It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.
In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss.
The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions.
Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Country | United States |
IPO Date | May 14, 2021 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 10,000 |
CEO | Kevin Ali |
Contact Details
Address: 30 Hudson Street Jersey City, New Jersey United States | |
Website | https://www.organon.com |
Stock Details
Ticker Symbol | OGN |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001821825 |
CUSIP Number | 68622V106 |
ISIN Number | US68622V1061 |
Employer ID | 46-4838035 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Kevin Ali | Chief Executive Officer & Director |
Matthew M. Walsh C.F.A. | Executive Vice President & Chief Financial Officer |
Aaron Falcione | Executive Vice President & Chief Human Resources Officer |
Daniel Karp | Head of Corporate Development |
Jennifer Halchak | Head of Investor Relations |
Joseph T. Morrissey Jr. | Executive Vice President and Head of Manufacturing & Supply |
Kirke Weaver | Executive Vice President, General Counsel & Corporate Secretary |
Rebecca Lowell Edwards | Chief Communications Officer |
Susan O'Neal | Chief Ethics & Compliance Officer |
Vittorio Nisita | Executive Vice President & Head of Global Business Services |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 28, 2025 | 10-K | Annual Report |
Feb 24, 2025 | 4 | Filing |
Feb 24, 2025 | 4 | Filing |
Feb 24, 2025 | 4 | Filing |
Feb 24, 2025 | 4 | Filing |
Feb 24, 2025 | 4 | Filing |
Feb 24, 2025 | 4 | Filing |
Feb 13, 2025 | 8-K | Current Report |
Jan 21, 2025 | 8-K | Current Report |
Dec 23, 2024 | 8-K | Current Report |